Extended adjuvant endocrine therapy in breast cancer

Current status and future directions

Paul Goss, Hyman Muss, James Ingle, Timothy Whelan, Melinda Wu

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Women with hormone receptor-positive breast cancer have traditionally been treated with 5 years of adjuvant tamoxifen to reduce their risk of subsequent recurrent disease. Among those who experience subsequent disease recurrence, the majority do so after 5 years, suggesting that longer durations of endocrine therapy might be beneficial. Two options tested include longer tamoxifen and, in postmenopausal women, a switch to an aromatase inhibitor (AI). In the National Cancer Institute of Canada Cooperative Trials Group MA.17 trial, we tested the AI letrozole given to postmenopausal women for 5 years after tamoxifen as extended adjuvant therapy because of its efficacy in patients with advanced breast cancer in progression on previous tamoxifen. The first interim analysis (median, 2.4 patient years) showed substantial benefits from letrozole, and all patients were unblinded and offered the option of letrozole. Despite two thirds of the patients crossing over to letrozole, an intent-to-treat analysis at 54 months' follow-up continued to demonstrate the strong beneficial effect of extended adjuvant letrozole. Furthermore, significant benefit was demonstrated among patients who had been randomized to placebo but elected to take letrozole after a prolonged washout from previous tamoxifen (late extended adjuvant therapy). A trial examining the merits of > 5 years of treatment with an AI, MA.17R, is ongoing, as are a number of other trials of duration of therapy. This article reviews results from MA.17 and the design of these trials of duration.

Original languageEnglish (US)
Pages (from-to)411-417
Number of pages7
JournalClinical Breast Cancer
Volume8
Issue number5
DOIs
StatePublished - Oct 1 2008

Fingerprint

letrozole
Tamoxifen
Breast Neoplasms
Aromatase Inhibitors
Therapeutics
National Cancer Institute (U.S.)
Canada
Direction compound
Placebos
Hormones

Keywords

  • Anastrozole
  • Aromatase inhibitors
  • Hormone receptor
  • Letrozole
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Extended adjuvant endocrine therapy in breast cancer : Current status and future directions. / Goss, Paul; Muss, Hyman; Ingle, James; Whelan, Timothy; Wu, Melinda.

In: Clinical Breast Cancer, Vol. 8, No. 5, 01.10.2008, p. 411-417.

Research output: Contribution to journalArticle

Goss, Paul ; Muss, Hyman ; Ingle, James ; Whelan, Timothy ; Wu, Melinda. / Extended adjuvant endocrine therapy in breast cancer : Current status and future directions. In: Clinical Breast Cancer. 2008 ; Vol. 8, No. 5. pp. 411-417.
@article{4eec5bd1b535405793d240a878938aee,
title = "Extended adjuvant endocrine therapy in breast cancer: Current status and future directions",
abstract = "Women with hormone receptor-positive breast cancer have traditionally been treated with 5 years of adjuvant tamoxifen to reduce their risk of subsequent recurrent disease. Among those who experience subsequent disease recurrence, the majority do so after 5 years, suggesting that longer durations of endocrine therapy might be beneficial. Two options tested include longer tamoxifen and, in postmenopausal women, a switch to an aromatase inhibitor (AI). In the National Cancer Institute of Canada Cooperative Trials Group MA.17 trial, we tested the AI letrozole given to postmenopausal women for 5 years after tamoxifen as extended adjuvant therapy because of its efficacy in patients with advanced breast cancer in progression on previous tamoxifen. The first interim analysis (median, 2.4 patient years) showed substantial benefits from letrozole, and all patients were unblinded and offered the option of letrozole. Despite two thirds of the patients crossing over to letrozole, an intent-to-treat analysis at 54 months' follow-up continued to demonstrate the strong beneficial effect of extended adjuvant letrozole. Furthermore, significant benefit was demonstrated among patients who had been randomized to placebo but elected to take letrozole after a prolonged washout from previous tamoxifen (late extended adjuvant therapy). A trial examining the merits of > 5 years of treatment with an AI, MA.17R, is ongoing, as are a number of other trials of duration of therapy. This article reviews results from MA.17 and the design of these trials of duration.",
keywords = "Anastrozole, Aromatase inhibitors, Hormone receptor, Letrozole, Tamoxifen",
author = "Paul Goss and Hyman Muss and James Ingle and Timothy Whelan and Melinda Wu",
year = "2008",
month = "10",
day = "1",
doi = "10.3816/CBC.2008.n.049",
language = "English (US)",
volume = "8",
pages = "411--417",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Extended adjuvant endocrine therapy in breast cancer

T2 - Current status and future directions

AU - Goss, Paul

AU - Muss, Hyman

AU - Ingle, James

AU - Whelan, Timothy

AU - Wu, Melinda

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Women with hormone receptor-positive breast cancer have traditionally been treated with 5 years of adjuvant tamoxifen to reduce their risk of subsequent recurrent disease. Among those who experience subsequent disease recurrence, the majority do so after 5 years, suggesting that longer durations of endocrine therapy might be beneficial. Two options tested include longer tamoxifen and, in postmenopausal women, a switch to an aromatase inhibitor (AI). In the National Cancer Institute of Canada Cooperative Trials Group MA.17 trial, we tested the AI letrozole given to postmenopausal women for 5 years after tamoxifen as extended adjuvant therapy because of its efficacy in patients with advanced breast cancer in progression on previous tamoxifen. The first interim analysis (median, 2.4 patient years) showed substantial benefits from letrozole, and all patients were unblinded and offered the option of letrozole. Despite two thirds of the patients crossing over to letrozole, an intent-to-treat analysis at 54 months' follow-up continued to demonstrate the strong beneficial effect of extended adjuvant letrozole. Furthermore, significant benefit was demonstrated among patients who had been randomized to placebo but elected to take letrozole after a prolonged washout from previous tamoxifen (late extended adjuvant therapy). A trial examining the merits of > 5 years of treatment with an AI, MA.17R, is ongoing, as are a number of other trials of duration of therapy. This article reviews results from MA.17 and the design of these trials of duration.

AB - Women with hormone receptor-positive breast cancer have traditionally been treated with 5 years of adjuvant tamoxifen to reduce their risk of subsequent recurrent disease. Among those who experience subsequent disease recurrence, the majority do so after 5 years, suggesting that longer durations of endocrine therapy might be beneficial. Two options tested include longer tamoxifen and, in postmenopausal women, a switch to an aromatase inhibitor (AI). In the National Cancer Institute of Canada Cooperative Trials Group MA.17 trial, we tested the AI letrozole given to postmenopausal women for 5 years after tamoxifen as extended adjuvant therapy because of its efficacy in patients with advanced breast cancer in progression on previous tamoxifen. The first interim analysis (median, 2.4 patient years) showed substantial benefits from letrozole, and all patients were unblinded and offered the option of letrozole. Despite two thirds of the patients crossing over to letrozole, an intent-to-treat analysis at 54 months' follow-up continued to demonstrate the strong beneficial effect of extended adjuvant letrozole. Furthermore, significant benefit was demonstrated among patients who had been randomized to placebo but elected to take letrozole after a prolonged washout from previous tamoxifen (late extended adjuvant therapy). A trial examining the merits of > 5 years of treatment with an AI, MA.17R, is ongoing, as are a number of other trials of duration of therapy. This article reviews results from MA.17 and the design of these trials of duration.

KW - Anastrozole

KW - Aromatase inhibitors

KW - Hormone receptor

KW - Letrozole

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=58149237894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149237894&partnerID=8YFLogxK

U2 - 10.3816/CBC.2008.n.049

DO - 10.3816/CBC.2008.n.049

M3 - Article

VL - 8

SP - 411

EP - 417

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 5

ER -